Home » Stocks » Homology Medicines

Homology Medicines, Inc. (FIXX)

Stock Price: $11.25 USD 0.68 (6.43%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 508.70M
Revenue (ttm) 2.16M
Net Income (ttm) -124.47M
Shares Out 45.22M
EPS (ttm) -2.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $11.25
Previous Close $10.57
Change ($) 0.68
Change (%) 6.43%
Day's Open 10.64
Day's Range 10.59 - 11.29
Day's Volume 242,997
52-Week Range 9.19 - 22.50

More Stats

Market Cap 508.70M
Enterprise Value 317.39M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 45.22M
Float 29.48M
EPS (basic) -2.78
EPS (diluted) -2.79
FCF / Share -2.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.43M
Short Ratio 9.58
Short % of Float 15.02%
Beta -0.26
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 235.62
PB Ratio 2.45
Revenue 2.16M
Operating Income -129.04M
Net Income -124.47M
Free Cash Flow -113.72M
Net Cash 191.31M
Net Cash / Share 4.23
Gross Margin -4,063.55%
Operating Margin -5,976.66%
Profit Margin -5,764.90%
FCF Margin -5,267.21%
ROA -26.91%
ROE -51.92%
ROIC -71.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 9
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(162.76% upside)
Current: $11.25
Target: 29.56
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-68.7%---
Gross Profit1.675.32--
Operating Income-110-59.93-29.66-10.00
Net Income-104-55.58-29.99-8.05
Shares Outstanding42.1228.552.481.90
Earnings Per Share-2.47-1.95-12.10-4.23
Operating Cash Flow-91.36-42.566.48-8.48
Capital Expenditures-21.83-24.94-1.96-1.99
Free Cash Flow-113-67.504.52-10.47
Cash & Equivalents26421713111.67
Net Cash / Debt26421713111.67
Book Value259196-39.45-9.89
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Homology Medicines, Inc.
Country United States
Employees 197
CEO Arthur O. Tzianabos

Stock Information

Ticker Symbol FIXX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FIXX


Homology Medicines, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.